Compounds > sch-48973
Page last updated: 2024-12-04

sch-48973

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1455
CHEMBL ID1235858
SCHEMBL ID8410512
MeSH IDM0522596

Synonyms (33)

Synonym
146949-21-5
CHEMBL1235858
1,3-dichloro-2-({4-[(2-chloro-4-methoxyphenoxy)methyl]benzyl}oxy)benzene
sch 48973
1,3-dichloro-2-[[4-[(2-chloro-4-methoxy-phenoxy)methyl]phenyl]methoxy]benzene
SC4 ,
1[2-chloro-4-methoxy-phenyl-oxymethyl]-4-[2,6-dichloro-phenyl-oxymethyl]-benzene
1,3-dichloro-2-[[4-[(2-chloro-4-methoxyphenoxy)methyl]phenyl]methoxy]benzene
v-073
sch-48973
unii-4ila3vov97
4ila3vov97 ,
benzene, 1-((2-chloro-4-methoxyphenoxy)methyl)-4-((2,6-dichlorophenoxy)methyl)-
pocapavir [inn]
pocapavir
1-((2-chloro-4-methoxyphenoxy)methyl)-4-((2,6-dichlorophenoxy)methyl)benzene
pocapavir [who-dd]
SCHEMBL8410512
CS-7839
DTXSID00163548
2-chloro-1-[[4-[(2,6-dichlorophenoxy)methyl]phenyl]methoxy]-4-methoxybenzene
sch-48973;v-073
HY-104074
1,3-dichloro-2-((4-((2-chloro-4-methoxyphenoxy)methyl)benzyl)oxy)benzene
ZB0039
BCP20876
N17010
benzene, 1-[(2-chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]-
Q27259647
MS-27445
AKOS037515600
WFA94921
AC-35788
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (87)

Assay IDTitleYearJournalArticle
AID563865Antiviral activity against Coxsackievirus serotype B4 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1562999Antiviral activity against Human rhinovirus clinical isolates relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563652Antiviral activity against Poliovirus 10224 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563861Antiviral activity against Coxsackievirus serotype A9 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563663Antiviral activity against Poliovirus 10220 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563847Antiviral activity against Poliovirus PV3-Leon serotype PV3 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563863Antiviral activity against Coxsackievirus serotype B2 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563868Antiviral activity against Enterovirus serotype 70 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563840Antiviral activity against Poliovirus MEF-1 serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563842Antiviral activity against Poliovirus PV2-P712 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563641Antiviral activity against Poliovirus 10690 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1562998Antiviral activity against Human rhinovirus clinical isolates2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563651Antiviral activity against Poliovirus 10225 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563662Antiviral activity against Poliovirus 10219 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445109Antiviral activity against Human rhinovirus A21 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID1563001Antiviral activity against Poliovirus assessed as reduction in virus induced cytopathic effect2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563838Antiviral activity against Poliovirus 10227 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1563000Antiviral activity against Human poliovirus 2 relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563664Antiviral activity against Poliovirus 10243 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563647Antiviral activity against Poliovirus 10668 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563646Antiviral activity against Poliovirus 10695 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563853Antiviral activity against Echovirus type 6 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563844Antiviral activity against Poliovirus 10805 serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563635Antiviral activity against Poliovirus 10238 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563656Antiviral activity against Poliovirus 10229 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563657Antiviral activity against Poliovirus 10230 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563850Cytotoxicity against human HeLa cells after 18 to 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563866Antiviral activity against Coxsackievirus serotype B5 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563856Antiviral activity against Echovirus type 7 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563659Antiviral activity against Poliovirus 10232 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445117Selectivity index, ratio of CC50 for human HeLa cells to EC50 for human poliovirus 3 infected in human HeLa cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563638Antiviral activity against Poliovirus 10240 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563841Antiviral activity against Poliovirus P712 serotype PV2 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563862Antiviral activity against Coxsackievirus serotype B1 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563650Antiviral activity against Poliovirus 10222 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563835Antiviral activity against Poliovirus 10221 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563640Antiviral activity against Poliovirus 10242 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563854Antiviral activity against Echovirus serotype 5 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563643Antiviral activity against Poliovirus 10692 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563648Antiviral activity against Poliovirus 10689 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563848Selectivity index, ratio of CC50 for human HeLa cells to EC50 for poliovirus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563846Antiviral activity against Poliovirus Leon serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445114Selectivity index, ratio of CC50 for human H1HeLa cells to EC50 for Human rhinovirus A71 infected in human H1HeLa cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563867Antiviral activity against Enterovirus serotype 68 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563636Antiviral activity against Poliovirus 10237 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563857Antiviral activity against Echovirus type 11 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563639Antiviral activity against Poliovirus 10241 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1573996Antiviral activity against Poliovirus Sabin 1 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by crystal violet staining-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.
AID563859Antiviral activity against Echovirus type 30 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563843Antiviral activity against Poliovirus 10804 serotype PV3 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563658Antiviral activity against Poliovirus 10231 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563661Antiviral activity against Poliovirus 10234 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1563002Antiviral activity against Poliovirus assessed as reduction in virus induced cytopathic effect relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563852Antiviral activity against Echovirus type 4 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563644Antiviral activity against Poliovirus 10693 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563864Antiviral activity against Coxsackievirus serotype B3 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563660Antiviral activity against Poliovirus 10233 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563642Antiviral activity against Poliovirus 10691 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563858Antiviral activity against Echovirus type 9 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563654Antiviral activity against Poliovirus Mahoney serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563837Antiviral activity against Poliovirus 10226 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445111Antiviral activity against Human rhinovirus A71 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563860Antiviral activity against Echovirus serotype 24 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1562974Antiviral activity against Human poliovirus 22019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563851Cytotoxicity against african green monkey BGMK cells after 18 to 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563649Antiviral activity against Poliovirus 10223 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563845Antiviral activity against Poliovirus Saukett serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445116Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563839Antiviral activity against Poliovirus Lansing serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1573997Antiviral activity against Poliovirus Sabin 2 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by crystal violet staining-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.
AID563637Antiviral activity against Poliovirus 10239 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563869Antiviral activity against Enterovirus serotype 71 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1573998Antiviral activity against Poliovirus Sabin 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 72 hrs by crystal violet staining-based assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.
AID563653Antiviral activity against Poliovirus Brunhilde serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563633Antiviral activity against Poliovirus 10235 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445113Selectivity index, ratio of CC50 for human H1HeLa cells to EC50 for Human rhinovirus A21 infected in human H1HeLa cells2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563855Antiviral activity against Echovirus serotype 3 infected in african green monkey BGMK cells assessed as inhibition of virus induced cytopathic effect after 18 to 24 hrs2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445115Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563655Antiviral activity against Poliovirus PV1-LSc/2ab serotype PV1 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445108Antiviral activity against Human rhinovirus B14 infected in human H1HeLa cells assessed as protection against virus induced cytopathic effect after 3 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563836Antiviral activity against Poliovirus 10228 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563645Antiviral activity against Poliovirus 10694 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1445110Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.
AID563870Solubility of the compound2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID1563003Antiviral activity against Poliovirus2019European journal of medicinal chemistry, Sep-15, Volume: 178Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.
AID563849Selectivity index, ratio of CC50 for african green monkey BGMK cells to EC50 for poliovirus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
AID563634Antiviral activity against Poliovirus 10236 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro antiviral activity of V-073 against polioviruses.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's1 (7.14)29.6817
2010's8 (57.14)24.3611
2020's3 (21.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews3 (20.00%)6.00%
Case Studies4 (26.67%)4.05%
Observational0 (0.00%)0.25%
Other7 (46.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pleconaril
WIN 63843: structure given in first source		4.4830
win 52035
Win 52035: structure given in first source		3.3110aromatic ether
win 52084
Win 52084: structure given in first source; RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 7/89		3.3110aromatic ether
oxazoles
Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.		3.27101,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
disoxaril
disoxaril: antipicornavirus agent		3.3110aromatic ether
pirodavir
pirodavir: antipicornavirus agent; structure given in first source		2.2110
r 61837
R 61837: antirhinovirus cpd; structure given in first source		3.3110
rupintrivir
rupintrivir: a rhinovirus 3C protease inhibitor		2.1510
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		3.2710
ConditionIndicatedRelationship StrengthStudiesTrials
Enterovirus Infections
Diseases caused by ENTEROVIRUS.		03.9240
Cerebromeningitis
[description not available]		02.8220
Carcinoma, Thymic
[description not available]		02.4110
Cancer of the Thymus
[description not available]		02.4110
Hypogammaglobulinemia
[description not available]		02.7220
Agammaglobulinemia
An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.		02.7220
Thymoma
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)		02.4110
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.4110
Genetic Diseases, X-Chromosome Linked
[description not available]		02.2510
Encephalitis, Polio
[description not available]		04.3841
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		04.3841
Health Care Associated Infection
[description not available]		03.0910
Infections, Picornaviridae
[description not available]		03.0910
Complications, Infectious Pregnancy
[description not available]		03.0910
Cross Infection
Any infection which a patient contracts in a health-care institution.		03.0910
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.0910
Diseases in Twins
Disorders affecting TWINS, one or both, at any age.		02.1710
Carditis
[description not available]		02.1710
Shock, Cardiogenic
Shock resulting from diminution of cardiac output in heart disease.		02.1710
Myocarditis
Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.		02.1710
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9910